344 results on '"Adrenomyeloneuropathy"'
Search Results
2. Home Exercise for Individuals With Neurodegenerative Disease
- Author
-
jennifer keller, Physical Therapist
- Published
- 2024
3. Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (MATRIX)
- Published
- 2024
4. The Myelin Disorders Biorepository Project (MDBP)
- Author
-
National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Advancing Translational Sciences (NCATS), Affinia Therapeutics, Biogen, Eli Lilly and Company, Homology Medicines, Inc, Myrtelle Inc., Orchard Therapeutics Ltd., Passage Bio, Inc., Synaptix Biotherapeutics Ltd., Takeda, Boehringer Ingelheim, Ionis Pharmaceuticals, Sanofi Winthrop Industrie, Sana Biotechnology, Inc., Yaya Foundation for 4H Leukodystrophy, University of Pennsylvania, and Adeline Vanderver, MD, Program Director, Leukodystrophy Center
- Published
- 2023
5. The pathology of X-linked adrenoleukodystrophy: tissue specific changes as a clue to pathophysiology
- Author
-
Hemmo A.F. Yska, Marc Engelen, and Marianna Bugiani
- Subjects
Adrenoleukodystrophy ,Adrenomyeloneuropathy ,Cerebral ALD ,Pathology ,Immunohistochemistry ,ABCD1 ,Medicine - Abstract
Abstract Although the pathology of X-linked adrenoleukodystrophy (ALD) is well described, it represents the end-stage of neurodegeneration. It is still unclear what cell types are initially involved and what their role is in the disease process. Revisiting the seminal post-mortem studies from the 1970s can generate new hypotheses on pathophysiology. This review describes (histo)pathological changes of the brain and spinal cord in ALD. It aims at integrating older works with current insights and at providing an overarching theory on the pathophysiology of ALD. The data point to an important role for axons and glia in the pathology of both the myelopathy and leukodystrophy of ALD. In-depth pathological analyses with new techniques could help further unravel the sequence of events behind the pathology of ALD.
- Published
- 2024
- Full Text
- View/download PDF
6. Patient-reported impact of symptoms in adrenoleukodystrophy (PRISM-ALD)
- Author
-
Anika Varma, Jennifer Weinstein, Jamison Seabury, Spencer Rosero, Nuran Dilek, John Heatwole, Charlotte Engebrecht, Shaweta Khosa, Kaitlin Chung, Asif Paker, Amy Woo, Gregory Brooks, Chan Beals, Rohan Gandhi, and Chad Heatwole
- Subjects
Adrenoleukodystrophy ,Adrenomyeloneuropathy ,Symptom ,Disease burden ,Qualitative research ,Patient interview ,Medicine - Abstract
Abstract Background Adrenoleukodystrophy (ALD) is a multifaceted, X-linked, neurodegenerative disorder that comprises several clinical phenotypes. ALD affects patients through a variety of physical, emotional, social, and other disease-specific factors that collectively contribute to disease burden. To facilitate clinical care and research, it is important to identify which symptoms are most common and relevant to individuals with any subtype of ALD. Methods We conducted semi-structured qualitative interviews and an international cross-sectional study to determine the most prevalent and important symptoms of ALD. Our study included adult participants with a diagnosis of ALD who were recruited from national and international patient registries. Responses were categorized by age, sex, disease phenotype, functional status, and other demographic and clinical features. Results Seventeen individuals with ALD participated in qualitative interviews, providing 1709 direct quotes regarding their symptomatic burden. One hundred and nine individuals participated in the cross-sectional survey study, which inquired about 182 unique symptoms representing 24 distinct symptomatic themes. The symptomatic themes with the highest prevalence in the overall ALD sample cohort were problems with balance (90.9%), limitations with mobility or walking (87.3%), fatigue (86.4%), and leg weakness (86.4%). The symptomatic themes with the highest impact scores (on a 0–4 scale with 4 being the most severe) were trouble getting around (2.35), leg weakness (2.25), and problems with balance (2.21). A higher prevalence of symptomatic themes was associated with functional disability, employment disruption, and speech impairment. Conclusions There are many patient-relevant symptoms and themes that contribute to disease burden in individuals with ALD. These symptoms, identified by those having ALD, present key targets for further research and therapeutic development.
- Published
- 2024
- Full Text
- View/download PDF
7. Novel ABCD1 variant causes phenotype of adrenomyeloneuropathy with cerebral involvement in Ukrainian siblings: first adult hematopoietic stem cell transplantation for ALD in Ukraine: a case report
- Author
-
Khrystyna Shchubelka, Olga Herasymenko, Andrii Budzyn, Oleksandr Lysytsia, Anastasiia Rusyn, Olga Oleksyk, Svitlana Tynta, and Taras Oleksyk
- Subjects
Adrenoleukodystrophy ,Adrenomyeloneuropathy ,ABCD1 gene ,Novel variant ,Hematopoietic stem cell transplant ,Medicine - Abstract
Abstract Background This article presents a case study of two white male siblings of 24 and 31 years of age of self-reported Ukrainian ethnicity diagnosed with adrenomyeloneuropathy (AMN) associated with a novel splice site mutation in the ABCD1 gene. AMN represents a form of X-linked adrenoleukodystrophy (X-ALD) characterized by demyelination of the spinal cord and peripheral nerves. The case also presents the first adult haematopoietic stem cell transplant (HSCT) for adrenomyeloneuropathy in Ukraine. The rarity of this mutation and its cerebral involvement and the treatment make this case noteworthy and underscore the significance of reporting it to contribute to the existing medical knowledge. Case presentation The patients of 24 and 31 years initially exhibited progressive gait disturbance, lower extremity pain, and urinary incontinence, with the older sibling experiencing more advanced symptoms of speech, hearing, and vision disturbances. A comprehensive genetic analysis identified an unreported splice site mutation in exon 3 of the ABCD1 gene, leading to the manifestation of AMN. The inheritance pattern was consistent with X-linked recessive transmission. The article also outlines the clinical features, magnetic resonance imaging (MRI), and nerve conduction study (NCS) findings. Moreover, it discusses the genetic profile of the affected individuals and female carriers within the family. The younger sibling underwent HSCT, which was complicated by mediastinal lymph node and lung tuberculosis, adding to the complexity of managing adult ALD patients. Conclusions This report emphasizes the importance of genetic testing in diagnosing and comprehending the underlying mechanisms of rare genetic disorders, such as AMN with cerebral involvement. The identification of a novel splice site mutation expands our understanding of the genetic landscape of this condition. Additionally, the challenges and complications encountered during the hematopoietic stem cell transplant procedure underscore the need for cautious consideration and personalized approaches in adult ALD patients.
- Published
- 2024
- Full Text
- View/download PDF
8. Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)
- Published
- 2023
9. The pathology of X-linked adrenoleukodystrophy: tissue specific changes as a clue to pathophysiology.
- Author
-
Yska, Hemmo A.F., Engelen, Marc, and Bugiani, Marianna
- Subjects
- *
ADRENOLEUKODYSTROPHY , *PATHOLOGICAL physiology , *PATHOLOGY , *X chromosome , *SPINAL cord , *TISSUES - Abstract
Although the pathology of X-linked adrenoleukodystrophy (ALD) is well described, it represents the end-stage of neurodegeneration. It is still unclear what cell types are initially involved and what their role is in the disease process. Revisiting the seminal post-mortem studies from the 1970s can generate new hypotheses on pathophysiology. This review describes (histo)pathological changes of the brain and spinal cord in ALD. It aims at integrating older works with current insights and at providing an overarching theory on the pathophysiology of ALD. The data point to an important role for axons and glia in the pathology of both the myelopathy and leukodystrophy of ALD. In-depth pathological analyses with new techniques could help further unravel the sequence of events behind the pathology of ALD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Patient-reported impact of symptoms in adrenoleukodystrophy (PRISM-ALD).
- Author
-
Varma, Anika, Weinstein, Jennifer, Seabury, Jamison, Rosero, Spencer, Dilek, Nuran, Heatwole, John, Engebrecht, Charlotte, Khosa, Shaweta, Chung, Kaitlin, Paker, Asif, Woo, Amy, Brooks, Gregory, Beals, Chan, Gandhi, Rohan, and Heatwole, Chad
- Subjects
- *
ADRENOLEUKODYSTROPHY , *MEDICAL registries , *MOBILITY of older people , *SYMPTOMS , *MEDICAL research , *NEURODEGENERATION - Abstract
Background: Adrenoleukodystrophy (ALD) is a multifaceted, X-linked, neurodegenerative disorder that comprises several clinical phenotypes. ALD affects patients through a variety of physical, emotional, social, and other disease-specific factors that collectively contribute to disease burden. To facilitate clinical care and research, it is important to identify which symptoms are most common and relevant to individuals with any subtype of ALD. Methods: We conducted semi-structured qualitative interviews and an international cross-sectional study to determine the most prevalent and important symptoms of ALD. Our study included adult participants with a diagnosis of ALD who were recruited from national and international patient registries. Responses were categorized by age, sex, disease phenotype, functional status, and other demographic and clinical features. Results: Seventeen individuals with ALD participated in qualitative interviews, providing 1709 direct quotes regarding their symptomatic burden. One hundred and nine individuals participated in the cross-sectional survey study, which inquired about 182 unique symptoms representing 24 distinct symptomatic themes. The symptomatic themes with the highest prevalence in the overall ALD sample cohort were problems with balance (90.9%), limitations with mobility or walking (87.3%), fatigue (86.4%), and leg weakness (86.4%). The symptomatic themes with the highest impact scores (on a 0–4 scale with 4 being the most severe) were trouble getting around (2.35), leg weakness (2.25), and problems with balance (2.21). A higher prevalence of symptomatic themes was associated with functional disability, employment disruption, and speech impairment. Conclusions: There are many patient-relevant symptoms and themes that contribute to disease burden in individuals with ALD. These symptoms, identified by those having ALD, present key targets for further research and therapeutic development. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Intrathecal administration of mesenchymal stem cells in patients with adrenomyeloneuropathy.
- Author
-
Siwek, Tomasz, Zwiernik, Beata, Jezierska-Woźniak, Katarzyna, Jezierska, Kamila, Mycko, Marcin P., and Selmaj, Krzysztof W.
- Subjects
MESENCHYMAL stem cells ,WALKING speed ,MUSCLE strength - Abstract
Background and objectives: X-linked adrenomyeloneuropathy (AMN) is an inherited neurodegenerative disorder associated with mutations in the ABCD1 gene and the accumulation of very long-chain fatty acids (VLFCAs) in plasma and tissues. Currently, there is no effective treatment for AMN. We have aimed to evaluate the therapeutic effects of mesenchymal stem cell (MSC) transplantation in patients with AMN. Methods: This is a small cohort open-label study with patients with AMN diagnosed and treated at the University Hospital in Olsztyn, Poland. All patients met clinical, biochemical, MRI, and neuropsychological criteria for AMN. MSCs derived from Wharton jelly, 20 × 106 cells, were administered intrathecally three times every 2 months, and patients were followed up for an additional 3 months. The primary outcome measures included a blinded assessment of lower limb muscle strength with the Medical Research Council Manual Muscle Testing scale at baseline and on every month visits until the end of the study. Additional outcomes included measurements of the timed 25-feet walk (T25FW) and VLFCA serum ratio. Results: Three male patients with AMN with an age range of 26-37 years participated in this study. All patients experienced increased muscle strength in the lower limbs at the end of the study versus baseline. The power grade increased by 25-43% at the baseline. In addition, all patients showed an improvement trend in walking speed measured with the T25FW test. Treatment with MSCs in patients with AMN appeared to be safe and well tolerated. Discussion: The results of this study demonstrated that intrathecal administration of WJ-MSC improves motor symptoms in patients with AMN. The current findings lend support to the safety and feasibility of MSC therapy as a potentially viable treatment option for patients with AMN. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Novel ABCD1 variant causes phenotype of adrenomyeloneuropathy with cerebral involvement in Ukrainian siblings: first adult hematopoietic stem cell transplantation for ALD in Ukraine: a case report.
- Author
-
Shchubelka, Khrystyna, Herasymenko, Olga, Budzyn, Andrii, Lysytsia, Oleksandr, Rusyn, Anastasiia, Oleksyk, Olga, Tynta, Svitlana, and Oleksyk, Taras
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *STEM cell transplantation , *HEMATOPOIETIC stem cells , *ADRENOLEUKODYSTROPHY , *NERVE conduction studies , *LYMPHADENITIS , *SPEECH apraxia - Abstract
Background: This article presents a case study of two white male siblings of 24 and 31 years of age of self-reported Ukrainian ethnicity diagnosed with adrenomyeloneuropathy (AMN) associated with a novel splice site mutation in the ABCD1 gene. AMN represents a form of X-linked adrenoleukodystrophy (X-ALD) characterized by demyelination of the spinal cord and peripheral nerves. The case also presents the first adult haematopoietic stem cell transplant (HSCT) for adrenomyeloneuropathy in Ukraine. The rarity of this mutation and its cerebral involvement and the treatment make this case noteworthy and underscore the significance of reporting it to contribute to the existing medical knowledge. Case presentation: The patients of 24 and 31 years initially exhibited progressive gait disturbance, lower extremity pain, and urinary incontinence, with the older sibling experiencing more advanced symptoms of speech, hearing, and vision disturbances. A comprehensive genetic analysis identified an unreported splice site mutation in exon 3 of the ABCD1 gene, leading to the manifestation of AMN. The inheritance pattern was consistent with X-linked recessive transmission. The article also outlines the clinical features, magnetic resonance imaging (MRI), and nerve conduction study (NCS) findings. Moreover, it discusses the genetic profile of the affected individuals and female carriers within the family. The younger sibling underwent HSCT, which was complicated by mediastinal lymph node and lung tuberculosis, adding to the complexity of managing adult ALD patients. Conclusions: This report emphasizes the importance of genetic testing in diagnosing and comprehending the underlying mechanisms of rare genetic disorders, such as AMN with cerebral involvement. The identification of a novel splice site mutation expands our understanding of the genetic landscape of this condition. Additionally, the challenges and complications encountered during the hematopoietic stem cell transplant procedure underscore the need for cautious consideration and personalized approaches in adult ALD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Adrenoleukodystrophy/Adrenomyeloneuropathy and Neurogenic Bladder Dysfunction. A Review
- Author
-
Khudyakova, N.V., Pchelin, I.Yu., Shishkin, A.N., Soloviev, O.V., and Smirnov, V.V.
- Subjects
adrenoleukodystrophy ,adrenomyeloneuropathy ,neurogenic bladder dysfunction ,Science ,Medicine ,History of scholarship and learning. The humanities ,AZ20-999 - Abstract
One of the conditions associated with adrenoleukodystrophy (ALD) / adrenomyeloneuropathy (AMN) is neurogenic lower urinary tract dysfunction (LUTD). A thorough examination of patients with ALD/AMN in most cases can reveal overactive bladder (OAB), which often remains undiagnosed because its clinical manifestations are underestimated against the background of numerous neurologic symptoms. In addition, in some cases, urologic symptomatology is the first sign of ALD/AMN that prompts the urologist to consider further evaluation of the patient. In this case, the urologist can play a significant role in the patient’s life, as timely diagnosis and treatment of ALD/AMN improve disease outcomes and reduce the likelihood of complications of ALD/AMN-associated conditions. To date, there are few studies devoted to the understanding of LUTD in ALD/AMN. In this article, we reviewed the current literature on OAB in patients with ALD/AMN.
- Published
- 2023
- Full Text
- View/download PDF
14. Intrathecal administration of mesenchymal stem cells in patients with adrenomyeloneuropathy
- Author
-
Tomasz Siwek, Beata Zwiernik, Katarzyna Jezierska-Woźniak, Kamila Jezierska, Marcin P. Mycko, and Krzysztof W. Selmaj
- Subjects
adrenomyeloneuropathy ,mesenchymal stem cells ,motor function ,WJ-MSC ,AMN ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Background and objectivesX-linked adrenomyeloneuropathy (AMN) is an inherited neurodegenerative disorder associated with mutations in the ABCD1 gene and the accumulation of very long-chain fatty acids (VLFCAs) in plasma and tissues. Currently, there is no effective treatment for AMN. We have aimed to evaluate the therapeutic effects of mesenchymal stem cell (MSC) transplantation in patients with AMN.MethodsThis is a small cohort open-label study with patients with AMN diagnosed and treated at the University Hospital in Olsztyn, Poland. All patients met clinical, biochemical, MRI, and neuropsychological criteria for AMN. MSCs derived from Wharton jelly, 20 × 106 cells, were administered intrathecally three times every 2 months, and patients were followed up for an additional 3 months. The primary outcome measures included a blinded assessment of lower limb muscle strength with the Medical Research Council Manual Muscle Testing scale at baseline and on every month visits until the end of the study. Additional outcomes included measurements of the timed 25-feet walk (T25FW) and VLFCA serum ratio.ResultsThree male patients with AMN with an age range of 26–37 years participated in this study. All patients experienced increased muscle strength in the lower limbs at the end of the study versus baseline. The power grade increased by 25–43% at the baseline. In addition, all patients showed an improvement trend in walking speed measured with the T25FW test. Treatment with MSCs in patients with AMN appeared to be safe and well tolerated.DiscussionThe results of this study demonstrated that intrathecal administration of WJ-MSC improves motor symptoms in patients with AMN. The current findings lend support to the safety and feasibility of MSC therapy as a potentially viable treatment option for patients with AMN.
- Published
- 2024
- Full Text
- View/download PDF
15. Plasma Exchange With Albumin in AMN Patients
- Published
- 2022
16. Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy
- Author
-
Jakub Antczak, Principal Investigator
- Published
- 2021
17. MicroRNA and metabolomics signatures for adrenomyeloneuropathy disease severity
- Author
-
Bela Rui Turk, Laila Marie Poisson, Christina Linnea Nemeth, Jordan Goodman, Ann B. Moser, Richard Owen Jones, Ali Fatemi, and Jaspreet Singh
- Subjects
adrenoleukodystrophy ,adrenomyeloneuropathy ,biomarker ,leukodystrophy ,metabolomics ,micro‐RNA ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 ,Genetics ,QH426-470 - Abstract
Abstract Adrenomyeloneuropathy (AMN), the slow progressive phenotype of adrenoleukodystrophy (ALD), has no clinical plasma biomarker for disease progression. This feasibility study aimed to determine whether metabolomics and micro‐RNA in blood plasma provide a potential source of biomarkers for AMN disease severity. Metabolomics and RNA‐seq were performed on AMN and healthy human blood plasma. Biomarker discovery and pathway analyses were performed using clustering, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and regression against patient's clinical Expanded Disability Status Score (EDSS). Fourteen AMN and six healthy control samples were analyzed. AMN showed strong disease‐severity‐specific metabolic and miRNA clustering signatures. Strong, significant clinical correlations were shown for 7‐alpha‐hydroxy‐3‐oxo‐4‐cholestenoate (7‐HOCA) (r2 = 0.83, p
- Published
- 2022
- Full Text
- View/download PDF
18. Two Single Nucleotide Deletions in the ABCD1 Gene Causing Distinct Phenotypes of X-Linked Adrenoleukodystrophy.
- Author
-
Dohr, Katrin A., Tokic, Silvija, Gastager-Ehgartner, Magdalena, Stojakovic, Tatjana, Dumic, Miroslav, Plecko, Barbara, and Dumic, Katja K.
- Subjects
- *
ADRENOLEUKODYSTROPHY , *DELETION mutation , *INBORN errors of metabolism , *ATP-binding cassette transporters , *ADDISON'S disease , *PHENOTYPES , *PROTEIN expression - Abstract
X-linked adrenoleukodystrophy (X-ALD) is a rare inborn error of the peroxisomal metabolism caused by pathologic variants in the ATP-binding cassette transporter type D, member 1 (ABCD1) gene located on the X-chromosome. ABCD1 protein, also known as adrenoleukodystrophy protein, is responsible for transport of the very long chain fatty acids (VLCFA) from cytoplasm into the peroxisomes. Therefore, altered function or lack of the ABCD1 protein leads to accumulation of VLCFA in various tissues and blood plasma leading to either rapidly progressive leukodystrophy (cerebral ALD), progressive adrenomyeloneuropathy (AMN), or isolated primary adrenal insufficiency (Addison's disease). We report two distinct single nucleotide deletions in the ABCD1 gene, c.253delC [p.Arg85Glyfs*18] in exon 1, leading to both cerebral ALD and to AMN phenotype in one family, and c.1275delA [p.Phe426Leufs*15] in exon 4, leading to AMN and primary adrenal insufficiency in a second family. For the latter variant, we demonstrate reduced mRNA expression and a complete absence of the ABCD1 protein in PBMC. Distinct mRNA and protein expression in the index patient and heterozygous carriers does not associate with VLCFA concentration in plasma, which is in line with the absence of genotype–phenotype correlation in X-ALD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Neurocognitive and mental health impact of adrenoleukodystrophy across the lifespan: Insights for the era of newborn screening.
- Author
-
Pierpont, Elizabeth I., Isaia, Ashley R., McCoy, Erin, Brown, Sarah J., Gupta, Ashish O., and Eisengart, Julie B.
- Abstract
X‐linked adrenoleukodystrophy (ALD) is a rare inherited neurological disorder that poses considerable challenges for clinical management throughout the lifespan. Although males are generally more severely affected than females, the time course and presentation of clinical symptoms are otherwise difficult to predict. Opportunities to improve outcomes for individuals with ALD are rapidly expanding due to the introduction of newborn screening programs for this condition and an evolving treatment landscape. The aim of this comprehensive review is to synthesize current knowledge regarding the neurocognitive and mental health effects of ALD. This review provides investigators and clinicians with context to improve case conceptualization, inform prognostic counseling, and optimize neuropsychological and mental health care for patients and their families. Results highlight key predictive factors and brain‐behavior relationships associated with the diverse manifestations of ALD. The review also discusses considerations for endpoints within clinical trials and identifies gaps to address in future research. To inform futureinvestigations, clinical trials, and multidisciplinary care practices, this comprehensive review synthesizes current knowledge regarding the neurocognitive and mental health effects of ALD across the lifespan. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Novel mutations in the ABCD1 gene caused adrenomyeloneuropathy in the Chinese population.
- Author
-
Raoli He, Jian Zhang, Tianwen Huang, Guoen Cai, Zhangyu Zou, and Qinyong Ye
- Subjects
CHINESE people ,ADRENOLEUKODYSTROPHY ,FAMILIAL spastic paraplegia ,GENETIC mutation ,GENETIC testing ,ADRENAL insufficiency - Abstract
Background: As a rare genetic disease, adrenomyeloneuropathy (AMN) is the most common adult phenotype of X-linked adrenoleukodystrophy (X-ALD). Mutations in the ABCD1 gene have been identified to cause AMN. Methods: We applied clinical evaluation, laboratory tests, and neuroimaging on three patients with progressive spastic paraparesis. In genetic analysis, we investigated ABCD1 gene mutations by whole-exome sequencing and Sanger sequencing. Bioinformatics tools were used to predict the eects of identified ABCD1 mutations on the protein. Results: All three patients were men with adult-onset disease, mainly characterized by progressive spastic paraparesis. Among them, two patients had peripheral neuropathy and one patient had signs of adrenal insufficiency. All three patients showed cerebral involvement on brain MRI, while two patients were found with diuse cord atrophy on spinal MRI. High-VLCFA levels in plasma, as well as C24:0/C22:0 and C26:0/C22:0 ratios, were found in all three patients. In addition, three dierent ABCD1 mutations were identified in three unrelated Chinese families, including one known mutation (c.1415_1416delAG) and two novel mutations (c.217C>T and c.160_170delACGCAGGAGGC). Based on the clinical assessment, radiographic, biochemical, and genetic testing, the final diagnosis was AMN in these patients with spastic paraparesis. Conclusion: This study reported three patients with AMN and identified two novel mutations in the ABCD1 in the Chinese population. Our finding emphasized that XALD is an important cause of adult-onset spastic paraplegia. Thus, neuroimaging, VLCFA testing, and especially the detection of the ABCD1 gene have important implications for the etiological diagnosis of adult patients with spastic paraplegia. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. The pressure time integral: An underused, clinically significant parameter as a determinant of neuropathic ulceration in diabetes.
- Author
-
Bartolo, Erica, Giacomozzi, Claudia, Coppini, David V., and Gatt, Alfred
- Subjects
- *
CHARCOT joints , *HEALING , *DIABETIC neuropathies , *ACRODYSTROPHIC neuropathy , *ADRENOMYELONEUROPATHY - Abstract
The purpose of this study was to evaluate plantar pressure dynamics in the occurrence of active diabetic neuropathic ulceration (DNU) and any changes in loadings occurring in individuals with a history of diabetic neuropathic ulceration (DHNU). Since current gold standard offloading strategies are not producing desirable healing outcomes and optimum ulcer prevention, this study aimed to better understand the effect of diabetic peripheral neuropathy (DPN) and ulceration on mean peak plantar pressure (MPPP) and pressure-time integral (PTI) changes. Is there a redistribution of plantar pressure during gait in the presence of active and history of diabetic neuropathic ulceration? A prospective, cross-sectional study was conducted, in which, eighty adult participants were divided into four groups, namely, the DM, DPN, DNU and DHNU groups. Participants were instructed to walk barefoot over a Tekscan HR Mat™ at self-selected speed. MPPP and PTI data were analysed under five forefoot anatomical landmarks and compared between individuals with and without active neuropathic ulceration. Minimal MPPP significant changes were observed between ulcerated and non-ulcerated groups, however, PTI values were significantly increased in the ulcerated groups under all plantar ulceration regions. No significant plantar pressure differences were observed between the DNU and DHNU groups. Logistic regression tests demonstrated that as PTIs under the hallux increase, the likelihood of an individual living with DPN developing ulceration increases. A significant increase in PTI values in the presence of ulceration highlights the importance of evaluating the duration of loads under forefoot regions during gait rather than just focusing on the magnitude of pressures during ulcer management and prevention. Moreover, results show that PTI values remain high in the presence of a history of neuropathic ulceration, possibly demonstrating the value of PTI as a clinical tool over MPPP in the assessment of the high-risk diabetic foot. • MPPP and PTI changes were analysed in the presence of active and history of neuropathic ulceration. • Minimal MPPP significant changes were observed. • Significant increase in PTI values detected under all plantar ulceration regions. • Evaluating duration of loads might be a better clinical tool for ulcer management and prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Functional electrical stimulation to aid walking in patients with adrenomyeloneuropathy: A case study and observational series
- Author
-
William Goodison, Fred Baron, Coralie Seary, Elaine Murphy, Robin Lachmann, and Valerie L. Stevenson
- Subjects
adrenomyeloneuropathy ,foot drop ,functional electrical stimulation ,walking satisfaction ,walking speed ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 ,Genetics ,QH426-470 - Abstract
Abstract Adrenomyeloneuropathy (AMN) is a rare inherited condition where affected individuals develop slowly progressive spastic paraparesis with a gradual decline in walking ability. There is no cure for AMN and treatment focuses on supportive measures and aids. One treatment option is functional electrical stimulation (FES), a treatment, approved by The National Institute for Health and Care Excellence (NICE), for managing foot drop in upper motor neuron disorders. Limited evidence exists for its use in AMN patients. We describe the effects of FES in an individual case and more broadly within a cohort of 21 patients successfully treated with FES. Patients with AMN referred for FES typically report frequent falls (71%) and foot drop (57%) as the most common barriers to walking. When using FES, walking speed at baseline (0.70 m/s [SD = 0.2]) was maintained at the 2‐year review (0.68 m/s [SD = 0.2]) with a persistent orthotic effect (improvement in walking speed when device on vs. off) seen from wearing FES over the same 2‐year period (11%–19%). Patient walking satisfaction (visual analogue scale: 0 – very dissatisfied; 10 – very satisfied) was also greater when comparing no‐FES versus FES over the same period (Year 1: 2.5 vs. 7.7; Year 2: 2.1 vs. 6.1). FES is not effective in all patients. Twelve patients referred found no benefit from the device; although there was no clear evidence, this was related to the degree of AMN associated peripheral neuropathy. However, FES is a safe, cost‐effective treatment option and should be considered, along with assessment in a multidisciplinary clinic, for all AMN patients with walking difficulties.
- Published
- 2022
- Full Text
- View/download PDF
23. Long-Term Disease Prevention with a Gene Therapy Targeting Oligodendrocytes in a Mouse Model of Adrenomyeloneuropathy.
- Author
-
Özgür-Günes, Yasemin, Chedik, Malha, Le Stunff, Catherine, Fovet, Claire-Maëlle, and Bougnères, Pierre
- Subjects
- *
GENE therapy , *OLIGODENDROGLIA , *GENE targeting , *CENTRAL nervous system diseases , *LABORATORY mice , *CERVICAL cord - Abstract
Adrenomyeloneuropathy (AMN) is a late-onset axonopathy of spinal cord tracts caused by mutations of the ABCD1 gene that encodes adrenoleukodystrophy protein (ALDP), a peroxisomal transporter of very long-chain fatty acids (VLCFA). Disturbed metabolic interaction between oligodendrocytes (OL) and axons is suspected to play a major role in AMN axonopathy. To develop a vector targeting OL, the human ABCD1 gene driven by a short 0.3 kb part of the human myelin-associated glycoprotein (MAG) promoter was packaged into an adeno-associated viral serotype 9 (rAAV9). An intravenous injection of this vector on postnatal day 10 in Abcd1−/− mice, a model of AMN, allowed a near normal motor performance to persist for 24 months, while age-matched untreated mice developed major defects of balance and motricity. Three weeks postvector, 50–54% of spinal cord white matter OL was expressing human ALDP (hALDP) at the cervical level, and only 6–7% after 24 months. In addition, 29–32% of cervical spinal cord astrocytes at 3 weeks and 16–19% at 24 months also expressed ALDP. C26:0-lysoPC, a sensitive VLCFA marker of AMN, was lower by 41% and 50%, respectively, in the spinal cord and brain of vector-treated compared with untreated mice. In a nonhuman primate, the intrathecal injection of the rAAV9-MAG vector induced abundant ALDP expression at 3 weeks in spinal cord OL (43%, 29%, and 26% at cervical, thoracic, and lumbar levels) and cerebellum OL (35%). In addition, 33–41% of spinal cord astrocytes expressed hALDP, and 27% of cerebellar astrocytes. To our knowledge, OL targeting had not been obtained before in primates with other vectors or promoters. The current results thus provide a robust proof-of-concept not only for the gene therapy of AMN but also for other central nervous system diseases, where the targeting of OL with the rAAV9-MAG vector may be of interest. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy (XAMNPIOP2011)
- Author
-
Instituto de Salud Carlos III, Fundacion Hesperia, and ELA España Association
- Published
- 2019
25. A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants
- Author
-
Ministerio de Sanidad, Servicios Sociales e Igualdad and Fundacion Hesperia
- Published
- 2019
26. A novel ABCD1 G1202A mutation in a Chinese patient with pure adrenomyeloneuropathy and literature review
- Author
-
Yu Zhang, Guoyong Zhang, Wenhui Chen, Zheng Pu, Lu Song, Xinghua Tang, and Zhenguo Liu
- Subjects
ABCD1gene ,Adrenomyeloneuropathy ,China ,Mutation ,Very-long-chain fatty acids ,Medicine (General) ,R5-920 ,Genetics ,QH426-470 - Abstract
Adrenomyeloneuropathy (AMN) is a kind of varied disease caused by ABCD1 gene mutation and characterized by very-long-chain fatty acids (VLCFA) accumulation. It is diagnosed by clinical features, high VLCFAs levels and ABCD1 gene mutation. AMN is rarely reported in Chinese population. In this study, we report the genetic and clinical features of a Chinese pure AMN patient. Meanwhile, we conducted a literature review of AMN cases to summarize the characteristics of AMN. We report a rare Chinese pure AMN case with slowly progressive weakness of the lower extremities, caused by a novel c.1202G > A mutation in ABCD1 gene. The literature review indicates that spastic paraplegia is the mainly clinical manifestation in patients with AMN. VLCFAs and ABCD1 gene test should be performed in patients with spastic paraplegia of the lower limbs to diagnose AMN.
- Published
- 2021
- Full Text
- View/download PDF
27. Psychometric Properties of the Scoliosis Research Society Questionnaire (Version 22r) Domains Among Adults With Spinal Deformity: A Rasch Measurement Theory Analysis.
- Author
-
Kyrölä, Kati, Hiltunen, Susanna, Uimonen, Mikko M., Ylinen, Jari, Häkkinen, Arja, and Repo, Jussi P.
- Subjects
- *
SPINAL cord diseases , *QUALITY of life , *SYMPTOMS , *ADRENOMYELONEUROPATHY , *MEDICAL care - Abstract
Objective: Adult spinal deformity (ASD) have lower health-related quality of life (HRQoL) compared to the general population. Applying Rasch measurement theory (RMT), this study tested the revised Scoliosis Research Society-22 (SRS-22r) HRQoL instrument among symptomatic adult patients with degenerative spinal disorders and varying degrees of ASD. Methods: SRS-22r data from 637 outpatient spine clinic patients with degenerative spine conditions were investigated for unidimensionality, item/scale fit, differential item functioning (DIF), scale coverage/targeting, and person separation index (PSI) using RMT. Results: Unidimensionality of the SRS-22r was not supported for either the total score or for 3 of its 5 domains. Item fit was acceptable for 11/22 items. The individual domains showed good coverage despite the degree of structural disorders. Ordered thresholds were achieved by merging response categories in some of the items. DIF towards age or sex was found in 11/22 items and in some domain items. The PSI exceeded 0.7 for the SRS-22r total score. Conclusion: The individual domain scores of the SRS-22r perform better than the total score providing good coverage and targeting among patients with ASD. Refinements of items and domains may improve the structural validity of the instrument to meet the criteria for measuring ASD patients, even when multidimensionality persists. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Typical and atypical phenotype and neuroimaging of X-linked adrenoleukodystrophy in a Chinese cohort.
- Author
-
Mao, Chenhui, Li, Jie, Huang, Xinying, Wang, Jie, Chu, Shanshan, Zhang, Yao, Dong, Liling, Liu, Caiyan, Lu, Lin, Qiu, Ling, Chen, Wei, Peng, Bin, Cui, Liying, and Gao, Jing
- Subjects
- *
GENOTYPES , *RESEARCH funding , *ADRENOLEUKODYSTROPHY , *PHENOTYPES , *NEURORADIOLOGY - Abstract
Objective: The objective of this study is to describe the typical and atypical clinical and neuroimaging features of ALD in Chinese patients, which will help early diagnosis and intervention to improve prognosis of ALD.Methods: Forty-one patients in the Leukoencephalopathy Clinic of Neurology Department, Peking Union Medical College Hospital were enrolled. Detailed clinical manifestations and MRI features were analyzed. The relationship between phenotype and genotype as well as biochemical analysis was observed.Results: The patients were classified according to phenotype and onset age, including 14 childhood cerebral ALD (CCALD), 8 adolescent cerebral ALD (adoCALD), 3 adult cerebral ALD (ACALD), 14 adrenomyeloneuropathy (AMN), and 2 ALD in women. AMN was the main presentation in adults. Visual impairment was usual onset symptom in CCALD and cognitive decline and psychiatric symptoms were found in adoCALD and ACALD. Typical MRI feature of CALD was symmetrical peri-ventricular "butterfly wings" like lesions in frontal and/or occipital lobe with peripheral DWI hyperintensities and Gd enhancement. Corpus callosum and internal capsule were always involved. Unilateral lesions were also possible. Cerebral AMN presented with centrum semiovale diffuse involvement. Spinocerebellar variant was a special subtype of AMN with obvious cerebellar and brainstem lesions. No relationships between phenotype and genotype as well as biochemical VLCFAs analysis were found.Conclusions: We emphasize that corpus callosum and internal capsule are always involved in ALD. A unilateral lesion is also possible. Neuroimaging of cerebral AMN is different from typical CALD with more centrum semiovale involvement. We support spinocerebellar variant was a rare subtype of AMN. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
29. Research from Intermountain Healthcare Provides New Study Findings on Adrenomyeloneuropathy (Burden of illness and mortality in men with Adrenomyeloneuropathy: a retrospective cohort study).
- Subjects
ADRENOLEUKODYSTROPHY ,PEROXISOMAL disorders ,BUSINESS insurance ,SENSORY ataxia ,HEALTH insurance - Abstract
A new report from Intermountain Healthcare provides research findings on adrenomyeloneuropathy (AMN), a neurodegenerative disease that is a phenotype of X-linked adrenoleukodystrophy (ALD). The study aimed to characterize the burden of illness and mortality in adult men with AMN in the US. The research found that men with AMN had higher healthcare utilization, greater medical comorbidity, higher mortality rates, and younger age at death compared to individuals without AMN. This study highlights the substantial health burden imposed by AMN on men. [Extracted from the article]
- Published
- 2024
30. Beyond gait and balance: urinary and bowel dysfunction in X-linked adrenoleukodystrophy
- Author
-
Camille S. Corre, Natalie Grant, Reza Sadjadi, Douglas Hayden, Catherine Becker, Pablo Gomery, and Florian S. Eichler
- Subjects
Adrenoleukodystrophy ,Adrenomyeloneuropathy ,Urinary dysfunction ,Bowel dysfunction ,Urodynamics ,Medicine - Abstract
Abstract Objective To characterize the prevalence, onset, and burden of urinary and bowel dysfunction in adult patients with adrenoleukodystrophy (ALD) and to evaluate any sex differences in symptom presentation. Methods In this retrospective and prospective study, we performed medical record review (n = 103), analyzed the results of clinically indicated urodynamic testing (n = 11), and developed and distributed a symptom and quality of life (QOL) survey (n = 59). Results Urinary and bowel symptoms are highly prevalent in both males (75.0%) and females (78.8%) in this population, most commonly urinary urgency, often leading to incontinence. Time to onset of first urinary or bowel symptom occurs approximately a decade earlier in males. Seventy-two percent of symptomatic patients report a limitation to QOL. Urodynamic evaluation provides evidence of three distinct mechanisms underlying lower urinary tract dysfunction: involuntary detrusor contractions (indicating uncontrolled neuronal stimulation with or without leakage), motor underactivity of the bladder, and asynergy between detrusor contraction and sphincter relaxation. Conclusions Beyond gait and balance difficulties, urinary and bowel symptoms are common in adults with ALD and impair QOL. Males are affected at a younger age but both sexes experience a higher symptom burden with age. As this population also experiences gait and balance impairment, patients with ALD are more vulnerable to urinary urgency leading to incontinence. Urodynamic evaluation may help better elucidate the pathophysiologic mechanisms underlying neurogenic lower urinary tract dysfunction, which can allow more targeted treatment.
- Published
- 2021
- Full Text
- View/download PDF
31. Two Single Nucleotide Deletions in the ABCD1 Gene Causing Distinct Phenotypes of X-Linked Adrenoleukodystrophy
- Author
-
Katrin A. Dohr, Silvija Tokic, Magdalena Gastager-Ehgartner, Tatjana Stojakovic, Miroslav Dumic, Barbara Plecko, and Katja K. Dumic
- Subjects
X-linked adrenoleukodystrophy ,adrenomyeloneuropathy ,pathogenic variant ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
X-linked adrenoleukodystrophy (X-ALD) is a rare inborn error of the peroxisomal metabolism caused by pathologic variants in the ATP-binding cassette transporter type D, member 1 (ABCD1) gene located on the X-chromosome. ABCD1 protein, also known as adrenoleukodystrophy protein, is responsible for transport of the very long chain fatty acids (VLCFA) from cytoplasm into the peroxisomes. Therefore, altered function or lack of the ABCD1 protein leads to accumulation of VLCFA in various tissues and blood plasma leading to either rapidly progressive leukodystrophy (cerebral ALD), progressive adrenomyeloneuropathy (AMN), or isolated primary adrenal insufficiency (Addison’s disease). We report two distinct single nucleotide deletions in the ABCD1 gene, c.253delC [p.Arg85Glyfs*18] in exon 1, leading to both cerebral ALD and to AMN phenotype in one family, and c.1275delA [p.Phe426Leufs*15] in exon 4, leading to AMN and primary adrenal insufficiency in a second family. For the latter variant, we demonstrate reduced mRNA expression and a complete absence of the ABCD1 protein in PBMC. Distinct mRNA and protein expression in the index patient and heterozygous carriers does not associate with VLCFA concentration in plasma, which is in line with the absence of genotype–phenotype correlation in X-ALD.
- Published
- 2023
- Full Text
- View/download PDF
32. MD1003-AMN MD1003 in Adrenomyeloneuropathy
- Published
- 2017
33. Restless Legs Syndrome in X-linked adrenoleukodystrophy.
- Author
-
Winkelman, John W., Grant, Natalie R., Molay, Francine, Stephen, Christopher D., Sadjadi, Reza, and Eichler, Florian S.
- Subjects
- *
RESTLESS legs syndrome , *ADRENOLEUKODYSTROPHY , *SLEEP interruptions , *SYMPTOMS , *MOTOR neuron diseases , *NEURODEGENERATION , *NEUROLOGIC examination , *PILOT projects , *RETROSPECTIVE studies , *SEVERITY of illness index , *QUALITY of life , *DISEASE prevalence , *RESEARCH funding , *DISEASE complications - Abstract
Objective/background: X-linked adrenoleukodystrophy (ALD) is a neurodegenerative disease that causes progressive gait and balance problems. Leg discomfort, sleep disturbances, and pain contribute to daily disability. We sought to investigate the prevalence and severity of Restless Legs Syndrome (RLS) in patients with ALD.Patients/methods: We administered questionnaires and conducted diagnostic telephone interviews to assess RLS severity. We retrospectively extracted data from neurological examinations, functional gait measures, and laboratory assessments.Results and Conclusions: Thirty-two adults with ALD (21 female, 11 male) were recruited to participate. Thirteen patients (40.6%) had RLS (10/21 females and 3/11 males). The median age of RLS onset was 35 years [IQR = 22-54]. Patients with RLS had more signs and symptoms related to myelopathy, but not the brain demyelination seen in ALD. This pilot study suggests a high prevalence of RLS in adults with ALD, which may contribute to sleep problems and impair quality of life. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
34. Investigating ABCD1 mutations in a Taiwanese cohort with hereditary spastic paraplegia phenotype.
- Author
-
Hsu, Shao-Lun, Chen, Ying-Hao, Chou, Cheng-Ta, Chou, Ying-Tsen, Tsai, Yu-Shuen, Hsiao, Cheng-Tsung, Liao, Yi-Chu, and Lee, Yi-Chung
- Subjects
- *
FAMILIAL spastic paraplegia , *PHENOTYPES , *GENETIC mutation , *SYMPTOMS , *PEROXISOMAL disorders , *TAIWANESE people - Abstract
Background: Adrenoleukodystrophy (ALD) is an X-linked peroxisomal disorder caused by mutations in the ABCD1 gene. The clinical manifestations of ALD vary widely with some patients presenting with adrenomyeloneuropathy (AMN) that resembles the phenotype of hereditary spastic paraplegia (HSP). The aim of this study is to investigate the frequency, spectrum, and clinical features of ABCD1 mutations in Taiwanese patients with HSP phenotype.Methods: Mutational analysis of the ABCD1 gene was performed in 230 unrelated Taiwanese patients with clinically suspected HSP by targeted resequencing. Clinical, electrophysiological, and neuroimaging features of the patients carrying an ABCD1 pathogenic mutation were characterized.Results: Ten different ABCD1 mutations were identified in eleven patients, including two novel mutations (p.Q177Pfs*17 and p.Y357*) and eight ever reported in ALD cases of other ethnicities. All patients were male and exhibited slowly progressive spastic paraparesis with onset ages ranging from 21 to 50 years. Most of them had additional non-motor symptoms, including autonomic dysfunction in nine patients, sensory deficits in seven, premature baldness in seven, skin hyperpigmentation in five, psychiatric symptoms in one and cerebellar ataxia in one. Seven of the ten patients who ever received nerve conduction studies showed axonal polyneuropathy. Magnetic resonance imaging (MRI) revealed diffuse spinal cord atrophy in seven patients, cerebral white matter hyperintensity in one patient, and cerebellar involvement in one patient.Conclusions: ABCD1 mutations account for 4.8% (11/230) of the cases with HSP phenotype in Taiwan. This study highlights the importance to consider ABCD1 mutations in patients with clinically suspected HSP of unknown genetic causes. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
35. Diverse clinical manifestations of X-linked adrenoleukodystrophy in a Chinese family with identical multisite variants of ABCD1 gene.
- Author
-
Zhang, Lin, Zhao, Su Li, and Wang, Zhi Hong
- Abstract
Objective: This study summarized the clinical characteristics of X-linked adrenoleukodystrophy (X-ALD) patients in this family, and two different manifestations of the same variants in a Chinese family were reported in this article. That conducted a follow-up study to further clarify the characteristics of this disease. Basic methods: Clinical data and test results were analyzed, and the exon region of ALD-related gene ABCD1 was sequenced by Sanger sequencing. Main results: Gene analysis showed that there were three ABCD1 variants in the proband, c.1047C>A, c.1415-1416delAG and c.1548G>A. The elder brother of the proband had the same three variants as the proband, but showed different clinical symptoms. The mother was the carrier of three variants. Multisite variants were uncovered in this family, which caused two different manifestations of adult-onset childhood cerebral ALD and adrenomyeloneuropathy. Principal conclusion: These findings further increase our knowledge about ABCD1 mutations and the associated phenotypes, which is beneficial for the genetic counseling of patients with X-ALD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
36. International validation of meaningfulness of postural sway and gait to assess myeloneuropathy in adults with adrenoleukodystrophy.
- Author
-
Yska HAF, Turk BR, Fatemi A, Goodman J, Voermans M, Amos D, Amanat M, van de Stadt S, Engelen M, Smith-Fine A, and Keller J
- Abstract
Background: The most common manifestation of X-linked adrenoleukodystrophy (ALD) is a slowly progressive myeloneuropathy, which leads to imbalance and gait disturbances. The variable progression of the disease complicates evaluation of its progression rate. Wearable sensors allow for easy and frequent balance and gait collection. This study reports baseline data from a longitudinal study on the quantitative assessment of balance and gait with wearable sensors and their clinical relevance., Methods: Data were collected from adult patients in two institutions. Postural body sway and gait parameters were measured using accelerometers. Disease severity was measured by the Expanded Disability Severity Scale (EDSS). Falling frequency and quality of life (QOL) were collected in men. The relationship between sway and gait variables and EDSS score, participants' use of a walking aid, and falling frequency was evaluated., Results: One hundred twenty individuals with ALD were included. Sway variables significantly differentiate participants' assistive device use. Sway and gait variables were correlated to the EDSS in both sexes. Both gait speed and sway were correlated with falling frequency in men from one institution. Select QOL subscores were correlated with the EDSS in males from one institution. Accelerometry generated comparable results across sites., Discussion: This study confirms the clinical correlation between spinal cord disease and imbalance and gait in ALD. For the first time, this study shows clinically meaningful relationships for sway and gait with use of an assistive device, falling frequency and QOL. Wearable accelerometers are a valid means to measure sway and gait in ALD. These measures are promising outcomes for clinical trial designs to assess myeloneuropathy in ALD and to monitor disease progression in individuals., (© 2024 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.)
- Published
- 2024
- Full Text
- View/download PDF
37. Adrenomyeloneuropathy with Later Development of Cerebral Form Caused by a Hemizygous Splice-site Variant in ABCD1.
- Author
-
Takegami N, Matsukawa T, Hamada M, Tanifuji S, Tamura T, Yamaguchi-Takegami N, Ishiura H, Mitsui J, Sakuishi K, Tsuji S, and Toda T
- Subjects
- Male, Humans, Middle Aged, Pedigree, RNA, Messenger genetics, ATP Binding Cassette Transporter, Subfamily D, Member 1 genetics, Adrenoleukodystrophy genetics, Adrenoleukodystrophy diagnosis, Adrenoleukodystrophy metabolism
- Abstract
Adrenomyeloneuropathy (AMN)/adrenoleukodystrophy (ALD) is an X-linked genetic disorder caused by pathogenic variants in ABCD1. We treated a 54-year-old man with slowly progressive spastic paraparesis with later development of the cerebral form. A pathogenic splice-site variant of ABCD1 (c.1489-1G>A, p.Val497Alafs*51) and elevated levels of very long-chain fatty acids were found, leading to the diagnosis of AMN. Detailed ABCD1 mRNA expression analyses revealed decreased levels of ABCD1 mRNA accompanied by deletion of the first 31 bp in exon 6. The altered mRNA transcriptional patterns associated with splice site variants are diverse and may provide important insights into ALD pathogenesis.
- Published
- 2024
- Full Text
- View/download PDF
38. Patent Issued for Compositions and methods for diagnosing and treating peroxisomal diseases (USPTO 12000843).
- Subjects
PEROXISOMAL disorders ,DIGESTIVE system diseases ,DIAGNOSIS ,NEUROLOGICAL disorders ,ADRENOLEUKODYSTROPHY - Abstract
A patent has been issued for compositions and methods for diagnosing and treating peroxisomal diseases. These diseases often involve the central nervous system and currently lack effective treatments. The invention involves identifying patients with active CNS disease and monitoring the course of the disease by measuring metallothioneins, which indicate a high risk of severe brain damage. The patent also includes methods for treating and identifying subjects at risk for peroxisomal diseases. [Extracted from the article]
- Published
- 2024
39. Reports from China-Japan Union Hospital of Jilin University Describe Recent Advances in Spastic Paraplegia (A novel ABCD1 gene mutation causes adrenomyeloneuropathy presenting with spastic paraplegia: A case report).
- Abstract
A recent report from the China-Japan Union Hospital of Jilin University describes a case of spastic paraplegia caused by a novel mutation in the ABCD1 gene. The patient, a 29-year-old male, presented with symptoms including progressive paraplegia, weakness of the lower limbs, fecal incontinence, and sexual dysfunction. Neuroimaging and genetic testing confirmed a diagnosis of X-linked adrenoleukodystrophy (X-ALD) with an adrenomyeloneuropathy (AMN) phenotype. The findings of this case expand our understanding of ABCD1 mutations and provide valuable information for genetic counseling and management of this X-linked disorder. [Extracted from the article]
- Published
- 2024
40. Studies Conducted at University of Tokyo on Adrenomyeloneuropathy Recently Reported (Adrenomyeloneuropathy With Later Development of Cerebral Form Caused By a Hemizygous Splice-site Variant In Abcd1).
- Abstract
A recent study conducted at the University of Tokyo in Japan focused on Adrenomyeloneuropathy (AMN), a genetic disorder caused by pathogenic variants in ABCD1. The researchers treated a 54-year-old man with slowly progressive spastic paraparesis and later development of the cerebral form of AMN. They identified a pathogenic splice-site variant of ABCD1 and elevated levels of very long-chain fatty acids, leading to the diagnosis of AMN. The study also revealed decreased levels of ABCD1 mRNA and altered mRNA transcriptional patterns associated with splice site variants, which may provide important insights into the pathogenesis of Adrenoleukodystrophy (ALD). [Extracted from the article]
- Published
- 2024
41. FATAL OUTCOME OF CERVICAL MYELOPATHY CAUSED BY FIBROCARTILAGINOUS EMBOLISM. RARE CAUSE OF SPINAL VASCULAR DAMAGE.
- Author
-
FOLYOVICH, András, HAVAS, László, VADÁSZ, Gizella, FEHÉR, Ágnes, VADASDI, Károly, SZABÓ, Zsolt, TÓTH, Kornélia, BÉRES-MOLNÁR, Katalin Anna, and TOLDI, Gergely
- Subjects
SPINAL cord diseases ,ADRENOMYELONEUROPATHY ,CERVICAL spondylotic myelopathy ,EMBOLISMS ,DIET therapy - Abstract
Copyright of Clinical Neuroscience / Ideggyógyászati Szemle is the property of LifeTime Media Kft. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
- Full Text
- View/download PDF
42. Clinical, neuroimaging, biochemical, and genetic features in six Chinese patients with Adrenomyeloneuropathy
- Author
-
Jie Li, Hongfen Wang, Zizi He, Xiangqing Wang, Jing Tang, and Dehui Huang
- Subjects
Adrenomyeloneuropathy ,Addison disease ,Spastic paraparesis ,Very long chain fatty acid ,ABCD1 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Background Adrenoleukodystrophy is a rare neurogenetic disease, AMN is the most common adult phenotype, such patients in China have not gotten enough attention. This article aims to study the features of AMN in Chinese patients and expand the gene spectrum of Chinese X-linked adrenoleukodystrophy (X-ALD) patients. Methods We applied clinical analysis, radiology, plasma levels of very long chain fatty acids (VLCFA) and genetic analysis to test the 6 Chinese AMN patients. Results All 6 patients are men. Ages of neurological symptom onset are distributed between 21 and 38. Sexual dysfunction occurred in 5 of 6 patients. Three patients had positive family history. Five patients had Addison’s disease. Four patients were diagnosed as pure AMN, while the other two patients were with cerebral involvement. Four patients had abnormalities of nerve conduction studies. There were four patients with central conduction defects in somatosensory evoked potential tests. All 6 patients were found diffuse cord atrophy in spinal MRI. Brain MRI showed abnormal signals in 2 of the 6 tested patients, which indicated the clinical phenotypes. Plasma levels of VLCFA, as well as C24:0/C22:0 and C26:0/C22:0 ratios were elevated in 5 tested patients. Five different ABCD1 mutations were identified in 5 tested patients, one of which was a de novo mutation, and the other four have been reported previously. Conclusion This research described the clinical, neuroimaging, biochemical, and genetic sides of Chinese AMN patients. A de novo mutation in the ABCD1 gene sequence was identified. Emotional trauma may trigger or aggravate the development of cerebral demyelination in AMN patients. Regular evaluation of brain MRI is important for AMN patients, especially for ‘pure AMN’ patients. When encountering patients with ‘myeloneuropathy-only’, neurologists should not ignore the tests of VLCFA or/and the ABCD1 gene.
- Published
- 2019
- Full Text
- View/download PDF
43. Newborn Screening for X-Linked Adrenoleukodystrophy in Nebraska: Initial Experiences and Challenges
- Author
-
Craig V. Baker, Alyssa Cady Keller, Richard Lutz, Karen Eveans, Krystal Baumert, James C. DiPerna, and William B. Rizzo
- Subjects
adrenoleukodystrophy ,adrenomyeloneuropathy ,newborn screening ,X-ALD ,ABCD1 ,peroxisomal fatty acid oxidation ,Pediatrics ,RJ1-570 - Abstract
X-linked adrenoleukodystrophy (X-ALD) is a neurodegenerative disease caused by pathogenic variants in ABCD1 resulting in defective peroxisomal oxidation of very long-chain fatty acids. Most male patients develop adrenal insufficiency and one of two neurologic phenotypes: a rapidly progressive demyelinating disease in mid-childhood (childhood cerebral X-ALD, ccALD) or an adult-onset spastic paraparesis (adrenomyeloneuropathy, AMN). The neurodegenerative course of ccALD can be halted if patients are treated with hematopoietic stem cell transplantation at the earliest onset of white matter disease. Newborn screening for X-ALD can be accomplished by measuring C26:0-lysophosphatidylcholine in dried blood spots. In Nebraska, X-ALD newborn screening was instituted in July 2018. Over a period of 3.3 years, 82,920 newborns were screened with 13 positive infants detected (4 males, 9 females), giving a birth prevalence of 1:10,583 in males and 1:4510 in females. All positive newborns had DNA variants in ABCD1. Lack of genotype-phenotype correlations, absence of predictive biomarkers for ccALD or AMN, and a high proportion of ABCD1 variants of uncertain significance are unique challenges in counseling families. Surveillance testing for adrenal and neurologic disease in presymptomatic X-ALD males will improve survival and overall quality of life.
- Published
- 2022
- Full Text
- View/download PDF
44. Nerve ultrasound characterizes AMN polyneuropathy as inhomogeneous and focal hypertrophic
- Author
-
Tim W. Rattay, Jennifer Just, Benjamin Röben, Holger Hengel, Rebecca Schüle, Matthis Synofzik, Anne S. Söhn, Natalie Winter, Nele Dammeier, Ludger Schöls, and Alexander Grimm
- Subjects
Adrenoleukodystrophy ,Adrenomyeloneuropathy ,X-ALD ,Nerve conduction study ,High resolution nerve ultrasound ,Very long chain fatty acids ,Medicine - Abstract
Abstract Objective High-resolution nerve ultrasound (HRUS) is a painless tool to quickly evaluate peripheral nerve morphology in vivo. This study set out to characterize peripheral nerve involvement in X-linked adrenomyeloneuropathy (AMN) by HRUS. Methods Thirteen adults with genetically proven AMN were examined using the Ultrasound pattern sum score (UPSS) to evaluate morphological abnormalities of peripheral nerves, vagal nerves, as well as cervical nerve roots. Ultrasound results were correlated with clinical findings and nerve conduction studies. Results UPSS was increased in six out of 13 patients. Nerve enlargement was mostly inhomogeneous and regional. The median, ulnar, and vagal nerves presented with more prominent alterations than nerves of the lower limbs. The proximal-to-distal ratio was significantly enlarged for the median nerve. HRUS findings matched nerve conduction studies, but identified one patient with enlarged nerves and yet normal conduction velocities. Sonographic findings did not correlate with disease duration or disease severity as assessed by the spastic paraplegia rating scale. Conclusion HRUS reveals significant multifocal regional nerve swellings with reduced echo intensity as the morphological equivalent of electrophysiological peripheral nerve affection in AMN patients. Ultrasound and NCS characteristics in AMN seem to differ from other demyelinating neuropathies like CIDP or CMT1a. Trial registration German clinical-trial-register (DRKS) (DRKS-ID 00005253) Registered 15 October 2013.
- Published
- 2018
- Full Text
- View/download PDF
45. Multiparametric in vivo analyses of the brain and spine identify structural and metabolic biomarkers in men with adrenomyeloneuropathy
- Author
-
Isaac M. Adanyeguh, Xiaofang Lou, Eavan McGovern, Marie-Pierre Luton, Magali Barbier, Elise Yazbeck, Romain Valabregue, Dinesh Deelchand, Pierre-Gilles Henry, and Fanny Mochel
- Subjects
Adrenomyeloneuropathy ,Spinal cord imaging ,Metabolite cycling ,Fixel-based analysis ,Imaging biomarkers ,Spinal cord toolbox ,Computer applications to medicine. Medical informatics ,R858-859.7 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Objective: Progressive myelopathy causes severe handicap in men with adrenomyeloneuropathy (AMN), an X-linked disorder due to ABCD1 pathogenic variants. At present, treatments are symptomatic but disease-modifying therapies are under evaluation. Given the small effect size of clinical scales in AMN, biomarkers with higher effect size are needed. Here we used high-resolution magnetic resonance techniques to identify non-invasive in vivo biomarkers of the brain and spine with high effect sizes. Methods: We performed a multiparametric imaging and spectroscopy study in 23 male patients with AMN (age: 44 ± 11) and 23 male controls (age: 43 ± 11) of similar age and body-mass index. We combined (i) macrostructural analyses of the spine, using cross-sectional area (CSA) and magnetization transfer ratio (MTR), (ii) microstructural analyses of the spine and the brain, using diffusion tensor and the newly developed fixel-based analysis, and (iii) advanced metabolic analyses of the spine using metabolite cycling coupled to a semi-LASER sequences. Results: Macrostructural alterations (decrease in CSA and MTR) were observed in patients at all spinal cord levels studied (C1-T2 for CSA and C1-C5 for MTR) (p
- Published
- 2021
- Full Text
- View/download PDF
46. X-linked adrenoleukodystrophy caused by a novel mutation presenting with various phenotypes in a Taiwanese family.
- Author
-
Chien, Chia-Yin, Chang, Kuo-Hsuan, and Chen, Chiung-Mei
- Subjects
- *
ADRENOLEUKODYSTROPHY , *PEROXISOMAL disorders , *ADDISON'S disease , *PHENOTYPES , *GENETIC mutation - Abstract
• X-linked adrenoleukodystrophy is caused by mutations in the gene, ABCD1. • p.Arg163Cys substitution caused by c.487C>T in exon 1 is a novel missense mutation. • There is no correlation between the genotype and phenotype of adrenoleukodystrophy. • Axonal neuropathy with multifocal demyelination is common in adrenoleukodystrophy. X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal disorder that primarily affects the white matter of central nervous system and the adrenal cortex. It is caused by mutations in the adenosine triphosphate-binding cassette, subfamily D, member 1 (ABCD1) gene that results in elevated plasma levels of very long chain fatty acids (VLCFAs). The disease is characterized by an unpredictable variation in phenotypic expressions, including childhood cerebral form (CCALD) and adrenomyeloneuropathy (AMN). Genetic analysis is a reliable method for the diagnosis of X-ALD. We reported a 46-year-old male admitted to Department of Neurology, Chang Gung Memorial Hospital with progressive paraparesis and Addison's disease, which was diagnosed when he was around 20-year-old. Plasma levels of VLCFA showed that his C26:0, C24:0/C22:0 and C26:0/C22:0 ratios were significantly elevated. A novel missense mutation (p.Arg163Cys) caused by the nucleotide change c.487C > T in exon 1 was identified in the ABCD1 gene of the proband and his subclinical family members. In this article, we reviewed the mutations that had been reported at the same position with different phenotypes. Given that the nerve conduction study (NCS) of the proband demonstrated a rare finding of demyelinating polyneuropathy with conduction blocks, we also reviewed the findings of NCS in patients with AMN in literature. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
47. Beyond gait and balance: urinary and bowel dysfunction in X-linked adrenoleukodystrophy.
- Author
-
Corre, Camille S., Grant, Natalie, Sadjadi, Reza, Hayden, Douglas, Becker, Catherine, Gomery, Pablo, and Eichler, Florian S.
- Subjects
- *
ADRENOLEUKODYSTROPHY , *SEX factors in disease , *URINARY organs , *ESOPHAGEAL motility , *MEDICAL records , *DEFECATION , *RESEARCH , *GAIT in humans , *RESEARCH methodology , *RETROSPECTIVE studies , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *QUALITY of life , *LONGITUDINAL method - Abstract
Objective: To characterize the prevalence, onset, and burden of urinary and bowel dysfunction in adult patients with adrenoleukodystrophy (ALD) and to evaluate any sex differences in symptom presentation.Methods: In this retrospective and prospective study, we performed medical record review (n = 103), analyzed the results of clinically indicated urodynamic testing (n = 11), and developed and distributed a symptom and quality of life (QOL) survey (n = 59).Results: Urinary and bowel symptoms are highly prevalent in both males (75.0%) and females (78.8%) in this population, most commonly urinary urgency, often leading to incontinence. Time to onset of first urinary or bowel symptom occurs approximately a decade earlier in males. Seventy-two percent of symptomatic patients report a limitation to QOL. Urodynamic evaluation provides evidence of three distinct mechanisms underlying lower urinary tract dysfunction: involuntary detrusor contractions (indicating uncontrolled neuronal stimulation with or without leakage), motor underactivity of the bladder, and asynergy between detrusor contraction and sphincter relaxation.Conclusions: Beyond gait and balance difficulties, urinary and bowel symptoms are common in adults with ALD and impair QOL. Males are affected at a younger age but both sexes experience a higher symptom burden with age. As this population also experiences gait and balance impairment, patients with ALD are more vulnerable to urinary urgency leading to incontinence. Urodynamic evaluation may help better elucidate the pathophysiologic mechanisms underlying neurogenic lower urinary tract dysfunction, which can allow more targeted treatment. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
48. Optical coherence tomography in adult adrenoleukodystrophy: a cross-sectional and longitudinal study.
- Author
-
Bianchi-Marzoli, Stefania, Fenu, Silvia, Melzi, Lisa, Benzoni, Chiara, Antonazzo, Filippo, Tomas Roldan, Eugenia, Farina, Laura, Tremolada, Gemma, Mauro, Elena, Pensato, Viviana, Gellera, Cinzia, Pareyson, Davide, and Salsano, Ettore
- Subjects
- *
OPTICAL coherence tomography , *LONGITUDINAL method , *ADRENOLEUKODYSTROPHY , *CROSS-sectional method , *ADULTS - Abstract
Background: Adrenoleukodystrophy (ALD) encompasses different neurological phenotypes, ranging from the most severe cerebral forms (C-ALD) to the less severe adrenomyeloneuropathy (AMN). As visual system can be varyingly involved, we aimed at exploring whether optical coherence tomography (OCT) may detect retinal abnormalities and their longitudinal changes in adult ALD patients. Methods: In this cross-sectional and longitudinal study, we measured the thicknesses of peripapillary retinal nerve fiber layer (pRNFL), macular ganglion cell complex (mGCC), and segmented inner and outer macula at baseline and their changes over time in 11 symptomatic adult ALD males and 10 age- and sex-matched healthy controls. Statistical analyses were performed for the patients as complete group, and splitting them into two subgroups, one (C-ALD) with and the other (AMN) without cerebral parieto-occipital white matter (WM) lesions. Results: In the complete ALD group and in the C-ALD subgroup, the average pRNFL, mGCC, and inner macula were significantly thinner than in controls (p ≤ 0.01), whereas in the AMN subgroup, they were constantly, though non-significantly, thinner. Significant outer macula thinning was also observed (p < 0.01). In the complete ALD group, follow-up assessment (mean 26.8 months, range 8–48) showed mildly progressive thinning of inferior pRNFL, average mGCC, and inner macula. Conclusions: In adult ALD patients, OCT can reveal retinal abnormalities which are prominent in the more compromised patients, namely those with parieto-occipital WM lesions. The inferior pRNFL, average mGCC and inner macula thicknesses might be sensitive-to-change OCT parameters, but their utility and consistency for short-term longitudinal studies deserve further investigations. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
49. A novel ABCD1 gene mutation causes adrenomyeloneuropathy in a Chinese family
- Author
-
Chao Wang, Hongchao Liu, Bing Han, Hui Zhu, and Jingyao Liu
- Subjects
ABCD1 ,adrenomyeloneuropathy ,Chinese family ,missense mutation ,X‐linked ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Abstract Background Adrenomyeloneuropathy (AMN) is a rare genetic disease. In this study, a case of AMN was uncovered in a Chinese family. Methods Clinical manifestations were collected and observed through medical records, physical examination, laboratory tests, and magnetic resonance imaging (MRI). Generation sequencing of the ABCD1 gene was performed, and the pedigree of the family was analyzed. Results The proband suffered from adrenocortical insufficiency at 8 years old and presented with a slowly progressive gait disorder at 21 years old. Physical examination, laboratory tests, and MRI showed that he had adult‐onset AMN manifestations, including spasticity and hyperactive tendon reflexes with Hoffman and Babinski signs in the limbs, difficulty in performing the heel‐to‐shin test, hyperpigmentation, increased levels of adrenocorticotropic hormone and very long‐chain fatty acids, decreased levels of corticosteroid and serum gesterol, and salient atrophy of the cervical and thoracic spinal cord. DNA analysis revealed a missense variant, c.290A>C (p.His97Pro) in exon 1 of the ABCD1 gene, in the proband. Sanger sequencing confirmed that the proband's mother was heterozygous for the same variant. The ABCD1 gene mutation transmitted in an X‐linked inheritance manner. Conclusion A novel missense mutation in the ABCD1 gene was identified in a Chinese family, which caused an unusual manifestation of adult‐onset AMN. This discovery is beneficial for the genetic counseling of patients with X‐linked adrenoleukodystrophy.
- Published
- 2019
- Full Text
- View/download PDF
50. Rare variability in adrenoleukodystrophy: a case report
- Author
-
Yanming Chen, Farhana Polara, and Anjana Pillai
- Subjects
Adrenoleukodystrophy ,Phenotypes ,Adrenomyeloneuropathy ,ABCD1 ,Medicine - Abstract
Abstract Background X-linked adrenoleukodystrophy is a genetic disorder with diverse clinical phenotypes. Of these phenotypes, the cerebral form usually manifests during early childhood with rapid cognitive and neurological deterioration and is accompanied by extensive white matter involvement. Adrenomyeloneuropathy, however, usually affects young adults and has focal symptoms typical of spinal cord and peripheral nerve involvement. Case presentation A 35-year-old African American man with a history of alcohol abuse presented with personality changes and lower extremity weakness. Diffuse demyelination was found on the brain image, and a diagnosis of the cerebral form was made based on the clinical features and genetic test. Conclusions We report a rare case of adult-onset cerebral X-linked leukodystrophy with a clinical phenotype of adrenomyeloneuropathy, and the diagnosis was confounded by a history of alcohol abuse.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.